The United Bio-technology (hengqin) Co., Ltd.

This Phase 3 trial tests a new injection called UBT251 in 360 adults with type 2 diabetes who have not been able to control their blood sugar with diet and exercise alone. Participants will receive either a weekly shot of UBT251 (at different doses) or a placebo for several weeks…

This phase 3 study compares an experimental weekly injection called UBT251 to the approved drug semaglutide in adults with type 2 diabetes whose blood sugar is not well controlled by oral medications like metformin. The main goal is to see if UBT251 is at least as effective as se…

This phase 3 study tests whether a weekly injection called UBT251 can help overweight or obese adults lose weight. Participants receive either the drug or a placebo for 52 weeks. The main goal is to measure the percentage change in body weight, with additional checks on waist siz…

This early-stage trial tests a single injection of UBT38006 in 43 healthy adult men to see if it is safe and how the body processes it. Participants receive either the drug, a placebo, or an active comparator (insulin degludec). The goal is to gather safety data and measure drug …